Should Income Investors Worry About Pfizer's Dividend?

September 12, 2026 - 17:41

Pfizer has become a popular topic among income focused investors, largely because its dividend yield sits near 6 percent. That is far above the average yield found in the broader market, and for retirees or anyone relying on steady cash flow, it is an attractive number. But there is a catch. The company's payout ratio is well over 100 percent, meaning it is paying out more in dividends than it earns. That is rarely a sustainable situation over the long run.

The reason Pfizer finds itself in this position comes down to a sharp drop in revenue following the peak of its COVID-19 product sales. Those sales delivered a massive windfall, and the company used that cash to fund buybacks, pay down debt, and support a generous dividend. Now that demand has fallen back to more normal levels, earnings have shrunk, and the payout has not been adjusted to match.

Management has signaled that it intends to keep the dividend intact for now. That is reassuring on the surface, but it raises a real question about priorities. If earnings do not recover, the company will have to fund the dividend from cash reserves, asset sales, or new borrowing. None of those options are ideal for long term financial health.

For income investors, the key issue is not whether the next payment arrives. It likely will. The question is whether the dividend can grow, or even hold steady, over the next several years. A yield this high often reflects market doubt rather than generosity. Investors should weigh that risk carefully before treating Pfizer as a reliable income holding.